# Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer

> **NCT00283608** · — · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 1000 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **GENETIC:** Single nucleotide polymorphism (SNP)
- **OTHER:** high performance liquid chromatography
- **OTHER:** measurements by DXA
- **OTHER:** questionnaire administration

## Key facts

- **NCT ID:** NCT00283608
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2011-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283608, "Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00283608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*